Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether UK-369,003 has improved their symptoms of overactive bladder and erectile function.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Male subjects aged 18 years and above

• documented clinical diagnosis of overactive bladder with urinary frequency >= 8 times / 24 hours and number of urgency episodes > 1 episode / 24 hours.

Exclusion Criteria:

• Neurological diseases known to affect bladder function.

• Urinary tract infection.